What is Beam Therapeutics's debt issuance proceeds?

Beam Therapeutics (BEAM) reported debt issuance proceeds of $93.89M in Q1 2026.

What does debt issuance proceeds mean?

Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.

Beam Therapeutics BEAM Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Arrowhead ResearchARWR

$3.16M—

Dyne Therapeutics, Inc.DYN

$49.45M—

BridgeBio PharmaBBIO

——

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.51B+24.5%

Enterprise value$3.47B+51.2%

P/S21.4×-23.0×

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromDebtNetOfIssuanceCosts.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's debt issuance proceeds?: Beam Therapeutics (BEAM) reported debt issuance proceeds of $93.89M in Q1 2026.
What does debt issuance proceeds mean?: Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.